|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neesse A, Algül H, Tuveson DA and Gress
TM: Stromal biology and therapy in pancreatic cancer: A changing
paradigm. Gut. 64:1476–1484. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cicenas J, Kvederaviciute K, Meskinyte I,
Meskinyte-Kausiliene E, Skeberdyte A and Cicenas J: KRAS, TP53,
CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer.
Cancers. 9:E422017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Komori T, Yagi H, Nomura S, Yamaguchi A,
Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al:
Targeted disruption of Cbfa1 results in a complete lack of
bone formation owing to maturational arrest of osteoblasts. Cell.
89:755–764. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Otto F, Thornell AP, Crompton T, Denzel A,
Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen
BR, et al: Cbfa1, a candidate gene for cleidocranial
dysplasia syndrome, is essential for osteoblast differentiation and
bone development. Cell. 89:765–771. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franceschi RT and Xiao G: Regulation of
the osteoblast-specific transcription factor, Runx2: Responsiveness
to multiple signal transduction pathways. J Cell Biochem.
88:446–454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chimge NO and Frenkel B: The RUNX family
in breast cancer: Relationships with estrogen signaling. Oncogene.
32:2121–2130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen-Solal KA, Boregowda RK and Lasfar A:
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving
force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozaki T, Wu D, Sugimoto H, Nagase H and
Nakagawara A: Runt-related transcription factor 2 (RUNX2) inhibits
p53-dependent apoptosis through the collaboration with HDAC6 in
response to DNA damage. Cell Death Dis. 4:e6102013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugimoto H, Nakamura M, Yoda H, Hiraoka K,
Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H and Ozaki T:
Silencing of RUNX2 enhances gemcitabine sensitivity of
p53-deficient human pancreatic cancer AsPC-1 cells through
the stimulation of TAp63-mediated cell death. Cell Death Discov.
6:e19142015. View Article : Google Scholar
|
|
14
|
Nakamura M, Sugimoto H, Ogata T, Hiraoka
K, Yoda H, Sang M, Sang M, Zhu Y, Yu M, Shimozato O and Ozaki T:
Improvement of gemcitabine sensitivity of p53-mutated
pancreatic cancer MiaPaCa-2 cells by RUNX2
depletion-mediated augmentation of TAp73-dependent cell death.
Oncogenesis. 5:e2332016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ozaki T, Nakamura M, Ogata T, Sang M, Yoda
H, Hiraoka K, Sang M and Shimozato O: Depletion of pro-oncogenic
RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated
pancreatic cancer Panc-1 cells through the induction of
pro-apoptotic TAp63. Oncotarget. 7:71937–71950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vousden KH and Lu X: Live or let die: The
cell's response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Melino G, De Laurenzi V and Vousden KH:
p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reynolds BA and Weiss S: Generation of
neurons and astrocytes from isolated cells of the adult mammalian
central nervous system. Science. 255:1707–1710. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hickman JA, Graeser R, de Hoogt R, Vidic
S, Brito C, Gutekunst M and van der Kuip H: IMI PREDECT Consortium:
Three-dimensional models of cancer for pharmacology and cancer cell
biology: Capturing tumor complexity in vitro/ex vivo.
Biotechnol J. 9:1115–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng L, Li D, Gu W, Liu A and Cheng X:
Formation of spherical cancer stem-like cell colonies with
resistance to chemotherapy drugs in the human malignant fibrous
histiocytoma NMFH-1 cell line. Oncol Lett. 10:3323–3331. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuo CT, Wang JY, Lin YF, Wo AM, Chen BPC
and Lee H: Three-dimensional spheroid culture targeting versatile
tissue bioassays using a PDMS-based hanging drop array. Sci Rep.
7:43632017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lissy NA, Davis PK, Irwin M, Kaelin WG and
Dowdy SF: A common E2F-1 and p73 pathway mediates cell death
induced by TCR activation. Nature. 407:642–645. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rossi M, Aqeilan RI, Neale M, Candi E,
Salomoni P, Knight RA, Croce CM and Melino G: The E3 ubiquitin
ligase Itch controls the protein stability of p63. Proc Natl Acad
Sci USA. 103:12753–12758. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren D, Wang M, Guo W, Zhao X, Tu S, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho JH, Kim SA, Park SB, Kim HM and Song
SY: Suppression of pancreatic adenocarcinoma upregulated factor
(PAUF) increases the sensitivity of pancreatic cancer to
gemcitabine and 5FU, and inhibits the formation of pancreatic
cancer stem like cells. Oncotarget. 8:76398–76407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao CC, Xu XL, Li F, Gong BG, Liu S, Cui
YQ, Sun HC, Xu PY, Zheng YM and Jiang H: Silencing pancreatic
adenocarcinoma upregulated factor (PAUF) increases the sensitivity
of pancreatic cancer cells to gemcitabine. Tumour Biol. 37:555–564.
2016. View Article : Google Scholar
|
|
28
|
Di Fiore R, Marcatti M, Drago-Ferrante R,
D'Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore
L, Tesoriere G and Vento R: Mutant p53 gain of function can be at
the root of dedifferentiation of human osteosarcoma MG63 cells into
3AB-OS cancer stem cells. Bone. 60:198–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Levy D, Reuven N and Shaul Y: A regulatory
circuit controlling Itch-mediated p73 degradation by Runx. J Biol
Chem. 283:27462–27468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hansen TM, Rossi M, Roperch JP, Ansell K,
Simpson K, Taylor D, Mathon N, Knight RA and Melino G: Itch
inhibition regulates chemosensitivity in vitro. Biochem
Biophys Res Commun. 361:33–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ogata T, Nakamura M, Sang M, Yoda H,
Hiraoka K, Yin D, Sang M, Shimozato O and Ozaki T: Depletion of
runt-related transcription factor 2 (RUNX2) enhances SAHA
sensitivity of p53-mutated pancreatic cancer cells through
the regulation of mutant p53 and TAp63. PLoS One. 12:e01798842017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang S, Quaresma AJ, Nickerson JA, Green
KM, Shaffer SA, Imbalzano AN, Martin-Buley LA, Lian JB, Stein JL,
van Wijnen AJ and Stein GS: Subnuclear domain proteins in cancer
cells support the functions of RUNX2 in the DNA damage response. J
Cell Sci. 128:728–740. 2015. View Article : Google Scholar : PubMed/NCBI
|
